Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

dabigatran

Boehringer, EFSD offer €2.5m in diabetes research grants

Application accepted up until April 1, 2013

- PMLiVE

FDA fast tracks two new lung cancer drugs

Boehringer’s afatinib and Roche/Astellas’ Tarveca receive accelerated review process

- PMLiVE

NICE set to approve Novartis eye drug Lucentis

Final draft guidance says treatment is cost-effective in diabetic macular oedema

- PMLiVE

Guidance for local formularies in England could improve uptake

NICE publishes recommendations to address variations

- PMLiVE

Government wants Prof David Haslam to be new NICE chair

He would take over from Prof Sir Michael Rawlins in April

- PMLiVE

Pfizer set for negative NICE decision on Inlyta

Institute's draft guidance doesn't recommend drug for advanced kidney cancer

- PMLiVE

BMS cuts Orencia price to win NICE over

Draft guidance now backs drug for earlier stage of rheumatoid arthritis treatment

- PMLiVE

NICE backs Servier’s heart failure drug Procoralan

But recommendation includes a number of restrictions that limit NHS use of the drug

- PMLiVE

Bayer’s Xarelto cleared in Europe for pulmonary embolism and DVT prevention

Gives further edge over Boehringer’s anticoagulant Pradaxa

- PMLiVE

NICE rejects Pierre Fabre’s bladder cancer drug Javlor

Says drug received final draft 'no' because pharma company failed to prove efficacy

- PMLiVE

Boehringer moves interferon-free hep C regimen into phase III

Oral combination drug achieved viral cure rate of up to 85 per cent in phase IIb

- PMLiVE

NICE to reverse approval for Novartis’ asthma drug Xolair

Draft guidance doesn't recommend omalizumab for severe asthma

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links